By CERBIOS-PHARMA SA
To get in touch with CERBIOS-PHARMA SA, simply fill out the form below.
Subscribe to Supplier
Cerbios-Pharma presents new PROVEO division at digital World ADC Europe 2021
Barbengo-Lugano, Switzerland: – Pharmaceutical ingredient specialist Cerbios-Pharma SA (Cerbios) will participate in World ADC Europe Digital Edition virtual conference during March 2021 with its PROVEO Division, a leading provider of services for ADC Development and Manufacturing. Members of PROVEO partner companies will also join the team at the PROVEO virtual booth.
Together, they will be at the PROVEO virtual exhibition booth presenting the end-to-end solutions for development and manufacturing of Antibody Drug Conjugates.
A major topic for conversation with visitors will be implications of recent reorganization of PROVEO, now entirely hosted as a division within Cerbios, which is now fully responsible for communication, logistics and program management.
The new organization is designed to help PROVEO handle its expanding business and client portfolio for the partners, that while simplifying the team interactions with clients will maintain the high level of integration between AGC Biologics and Oncotec Pharma Produktion, PROVEO partners.
Integrated ADC solution
Cerbios-Pharma will also contribute to the event agenda with a presentation on ‘PROVEO: integrated solution for ADC manufacturing’, to be delivered by Business Development Manager, Dr. Vítor Sousa.
Dr. Sousa, whose background includes 15 years’ experience in CDMOs dedicated to clinical development and manufacturing of biotherapeutic products, has played senior roles in Cerbios Biotechnology and Bioconjugation teams.
Tailored service and simplified supply
He will present how the PROVEO ADC offer includes a tailored service platform with clear and flexible contractual framework, delivering a simplified supply chain from sourcing Key Starting Materials to manufacturing and Fill & Finish activities.
Dr. Sousa will also highlight importance of a completely integrated Project Management system, coordinated Quality System, and supporting manufacturing network in the PROVEO ADC platform.
Dr. Sousa will be supported by Cerbios-Pharma R&D Director, Alberto Terraneo, and Deputy Director of Business Development for Oncotec Pharma Produktion GmbH, Matthias Beck, in participating in networking across the event.
Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacturing of both chemical and biological APIs for its partners world-wide.
Exclusive CDMO services are offered for the development and manufacturing of high potency active ingredients (HPAIs) as well as for biological products including monoclonal antibodies, recombinant proteins and antibody drug conjugates (ADCs).
Cerbios provides full CMC support, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs, with paramount ability to support a successful registration. Cerbios is a worldwide presence with partners in Europe, USA and Japan.
Cerbios Division, PROVEO™, in partnership with AGC Biologics and Oncotec, focus on integrated ADC manufacturing solutions.
PROVEO can offer a ADCs end-to-end service from drug substance development till sterile Fill & Finish.
Learn more at: https://cerbios.swiss
About World ADC Europe Digital 2021
The World ADC Conference series form the pharma industry’s longest standing and most comprehensive set of events devoted to Antibody Drug Conjugate (ADC) technology and solutions.
Now in its 11th year, World ADC Europe brands itself as the industry-leading conference to help forward thinking researchers from the pharmaceutical, biotech and academic community advance the development of ADCs.
The 2021 Digital Edition event, devoted to Maximizing the Clinical Therapeutic Window of Antibody-drug Conjugates, is a virtual conference hosted online over four days, opening 8th March, 2021.
It will feature contributions and participation from experts drawn from more than 140 organisations active in the ADCs sector, considering a range of topics that include the approval of Trodelvy from Immunomedics, Blenrep from GSK – and ADC Therapeutics submission of BLA in September 2020.
The event is organized by Hanson Wade with more information at: https://worldadc-europe.com.